-
公开(公告)号：US09090712B2
公开(公告)日：2015-07-28
申请号：US12536975
申请日：2009-08-06
Applicant: Ingegerd Hellstrom , Jeffrey A. Ledbetter , Martha Hayden-Ledbetter
Inventor： Ingegerd Hellstrom , Jeffrey A. Ledbetter , Martha Hayden-Ledbetter
IPC: C07K14/435 , C07K19/00 , C07K14/81 , C07K16/18 , C07K16/30 , C07K16/40 , G01N33/574 , G01N33/53 , A61K39/00
CPC classification number: G01N33/57449 , A61K2039/505 , C07K14/811 , C07K16/18 , C07K16/30 , C07K16/3069 , C07K16/40 , C07K2319/00 , C07K2319/30 , G01N33/57488 , G01N2333/705
Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.
-
公开(公告)号：US20140141022A1
公开(公告)日：2014-05-22
申请号：US13815721
申请日：2013-03-15
Applicant: PETER ARMSTRONG THOMPSON , JEFFREY A. LEDBETTER , MARTHA SUSAN HAYDEN-LEDBETTER , LAURA SUE GROSMAIRE , ROBERT BADER , WILLIAM BRADY
Inventor： PETER ARMSTRONG THOMPSON , JEFFREY A. LEDBETTER , MARTHA SUSAN HAYDEN-LEDBETTER , LAURA SUE GROSMAIRE , ROBERT BADER , WILLIAM BRADY
IPC: C07K16/18
CPC classification number: C07K16/28 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/2803 , C07K16/2809 , C07K16/2818 , C07K16/2827 , C07K16/2833 , C07K16/2851 , C07K16/2875 , C07K16/2878 , C07K16/2887 , C07K16/2896 , C07K16/30 , C07K16/46 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2319/30
Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.
Abstract translation: 提供具有免疫球蛋白效应子功能的多价结合肽，包括双特异性结合肽，以及编码核酸，载体和宿主细胞以及制备这些肽的方法和使用这些肽治疗或预防各种疾病的方法 ，疾病或病症，以及改善与这种疾病，病症或病症相关的至少一种症状。
-
公开(公告)号：US08197810B2
公开(公告)日：2012-06-12
申请号：US12901297
申请日：2010-10-08
Applicant: Jeffrey A. Ledbetter , Martha Susan Hayden-Ledbetter
Inventor： Jeffrey A. Ledbetter , Martha Susan Hayden-Ledbetter
IPC: A61K39/395
CPC classification number: C07K16/46 , A61K2039/505 , C07K16/2809 , C07K16/2818 , C07K16/2878 , C07K16/2896 , C07K16/462 , C07K2317/22 , C07K2317/24 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/30
Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.
Abstract translation: 本发明涉及新颖的结合域 - 免疫球蛋白融合蛋白，其特征在于同源结构如结合抗原，反式受体等的结合结构域，具有零个或一个半胱氨酸残基的铰链区多肽和免疫球蛋白CH2和CH3结构域， 并且其能够主要以单体多肽的形式存在于ADCC和/或CDC。 可以以高表达水平重组产生融合蛋白。 还提供了相关的组合物和方法，包括免疫治疗应用。
-
公开(公告)号：US20120034245A9
公开(公告)日：2012-02-09
申请号：US12304562
申请日：2007-06-12
Applicant: Peter Armstrong Thompson , Jeffrey A. Ledbetter , Martha Susan Hayden-Ledbetter , Laura Sue Grosmaire , Robert Bader , William Brady
Inventor： Peter Armstrong Thompson , Jeffrey A. Ledbetter , Martha Susan Hayden-Ledbetter , Laura Sue Grosmaire , Robert Bader , William Brady
IPC: A61K39/395 , C07K16/46 , C07H21/00 , C12N15/63 , C12N5/10 , A61P37/06 , A61P29/00 , A61P3/10 , A61P19/02 , A61P11/06 , A61P25/00 , A61P17/06 , C07K19/00 , A61P35/00
CPC classification number: C07K16/28 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/2803 , C07K16/2809 , C07K16/2818 , C07K16/2827 , C07K16/2833 , C07K16/2851 , C07K16/2875 , C07K16/2878 , C07K16/2887 , C07K16/2896 , C07K16/30 , C07K16/46 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2319/30
Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.
Abstract translation: 提供具有免疫球蛋白效应子功能的多价结合肽，包括双特异性结合肽，以及编码核酸，载体和宿主细胞以及制备这些肽的方法和使用这些肽治疗或预防各种疾病的方法 ，疾病或病症，以及改善与这种疾病，病症或病症相关的至少一种症状。
-
公开(公告)号：US20100203052A1
公开(公告)日：2010-08-12
申请号：US12724333
申请日：2010-03-15
Applicant: Jeffrey A. Ledbetter , Martha S. Hayden-Ledbetter
Inventor： Jeffrey A. Ledbetter , Martha S. Hayden-Ledbetter
IPC: A61K39/395 , A61P29/00 , A61P3/10 , A61P17/06 , A61P1/04
CPC classification number: C07K16/3061 , A61K38/00 , A61K39/0011 , A61K2039/505 , A61K2039/5152 , A61K2039/5156 , A61K2039/5158 , C07K16/2809 , C07K16/2818 , C07K16/2878 , C07K16/2896 , C07K16/462 , C07K2317/22 , C07K2317/24 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/30 , C12N5/0636 , C12N2501/23 , C12N2501/51 , C12N2501/515 , C12N2501/52 , C12N2502/11 , C12N2510/00
Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high express levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.
-
Patent Agency Ranking
公开(公告)号：US07754208B2
公开(公告)日：2010-07-13
申请号：US10207655
申请日：2002-07-25
Applicant: Jeffrey A Ledbetter , Martha S Hayden-Ledbetter
Inventor： Jeffrey A Ledbetter , Martha S Hayden-Ledbetter
CPC classification number: C07K16/3061 , A61K38/00 , A61K39/0011 , A61K2039/505 , A61K2039/5152 , A61K2039/5156 , A61K2039/5158 , C07K16/2809 , C07K16/2818 , C07K16/2878 , C07K16/2896 , C07K16/462 , C07K2317/22 , C07K2317/24 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/30 , C12N5/0636 , C12N2501/23 , C12N2501/51 , C12N2501/515 , C12N2501/52 , C12N2502/11 , C12N2510/00
Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.
Abstract translation: 本发明涉及新颖的结合域 - 免疫球蛋白融合蛋白，其特征在于用于诸如抗原，反向受体等的同源结构的结合结构域，野生型IgG1，IGA或IgE铰链区多肽或突变IgG1铰链区多肽 具有零个，一个或两个半胱氨酸残基，以及免疫球蛋白CH2和CH3结构域，并且它们能够以ADCC和/或CDC的形式发生，同时主要作为其形成二硫键连接的多聚体的能力被损害的多肽。 可以以高表达水平重组产生融合蛋白。 还提供了相关的组合物和方法，包括融合蛋白的细胞表面形式和融合蛋白的免疫治疗应用以及编码这种融合蛋白的多核苷酸。
-
公开(公告)号：US20100034820A1
公开(公告)日：2010-02-11
申请号：US12541062
申请日：2009-08-13
Applicant: Jeffrey A. Ledbetter , Martha Hayden-Ledbetter , Peter A. Thompson
Inventor： Jeffrey A. Ledbetter , Martha Hayden-Ledbetter , Peter A. Thompson
IPC: A61K39/395 , C07K16/00
CPC classification number: C07K16/3061 , A61K38/00 , A61K39/0011 , A61K2039/505 , A61K2039/5152 , A61K2039/5156 , A61K2039/5158 , C07K16/2809 , C07K16/2818 , C07K16/2878 , C07K16/2896 , C07K16/462 , C07K2317/22 , C07K2317/24 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/30 , C12N5/0636 , C12N2501/23 , C12N2501/51 , C12N2501/515 , C12N2501/52 , C12N2502/11 , C12N2510/00
Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high express levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.
Abstract translation: 本发明涉及新颖的结合域 - 免疫球蛋白融合蛋白，其特征在于用于诸如抗原，反向受体等的同源结构的结合结构域，野生型IgG1，IGA或IgE铰链区多肽或突变IgG1铰链区多肽 具有零个，一个或两个半胱氨酸残基，以及免疫球蛋白CH2和CH3结构域，并且它们能够以ADCC和/或CDC的形式发生，同时主要作为其形成二硫键连接的多聚体的能力被损害的多肽。 融合蛋白可以以高表达水平重组产生。 还提供了相关的组合物和方法，包括融合蛋白的细胞表面形式和融合蛋白的免疫治疗应用以及编码这种融合蛋白的多核苷酸。
-
公开(公告)号：US07572772B2
公开(公告)日：2009-08-11
申请号：US11725384
申请日：2007-03-19
Applicant: Peter S. Linsley , Jeffrey A. Ledbetter , Nitin K. Damle , William Brady , Philip M. Wallace
Inventor： Peter S. Linsley , Jeffrey A. Ledbetter , Nitin K. Damle , William Brady , Philip M. Wallace
IPC: C07K14/705
CPC classification number: C07K16/247 , A61K38/00 , A61K2039/505 , C07K14/70521 , C07K14/7155 , C07K16/00 , C07K16/2818 , C07K16/2827 , C07K2317/34 , C07K2317/73 , C07K2319/00 , C07K2319/30 , Y10S514/885
Abstract: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
Abstract translation: 本发明鉴定CTLA4受体作为B7抗原的配体。 提供编码人CTLA4受体基因的完整氨基酸序列。 提供用于表达CTLA4作为免疫球蛋白融合蛋白的方法，用于制备杂合CTLA4融合蛋白，并使用可溶性融合蛋白，其片段和衍生物，包括与B7和CTLA4反应的单克隆抗体调节T细胞相互作用和免疫应答介导 通过这种互动。
-
公开(公告)号：US20090104684A1
公开(公告)日：2009-04-23
申请号：US11890896
申请日：2007-08-08
Applicant: Michel Schummer , INGEGERD HELLSTROM , Karl Erik Hellstrom , JEFFREY A. LEDBETTER , MARTHA HAYDEN-LEDBETTER
Inventor： Michel Schummer , INGEGERD HELLSTROM , Karl Erik Hellstrom , JEFFREY A. LEDBETTER , MARTHA HAYDEN-LEDBETTER
CPC classification number: G01N33/57449 , A61K2039/505 , C07K14/811 , C07K16/18 , C07K16/30 , C07K16/3069 , C07K16/40 , C07K2319/00 , C07K2319/30 , G01N33/57488 , G01N2333/705
Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.
Abstract translation: 本发明涉及用于检测恶性病症的组合物和方法，并且涉及HE4a多肽的可溶性和细胞表面形式的发现，包括在卵巢癌中过表达的HE4a。 特别地，本发明提供了编码HE4a的核酸序列，并且还提供了通过检测对具有天然存在于可溶性和/或可溶性的分子的HE4a多肽的特异性抗体的反应性来筛选受试者中恶性病症的存在的方法。 来自这样的受试者的样品中的细胞表面形式，以及使用HE4a核苷酸序列的杂交筛选以及其它相关优点。
-
公开(公告)号：US07270960B2
公开(公告)日：2007-09-18
申请号：US10233150
申请日：2002-08-28
Applicant: Ingegerd Hellstrom , Jeffrey A. Ledbetter , Martha Hayden-Ledbetter
Inventor： Ingegerd Hellstrom , Jeffrey A. Ledbetter , Martha Hayden-Ledbetter
CPC classification number: G01N33/57449 , A61K2039/505 , C07K14/811 , C07K16/18 , C07K16/30 , C07K16/3069 , C07K16/40 , C07K2319/00 , C07K2319/30 , G01N33/57488 , G01N2333/705
Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.
Abstract translation: 本发明涉及用于检测恶性病症的组合物和方法，并且涉及HE4a多肽的可溶性和细胞表面形式的发现，包括在卵巢癌中过表达的HE4a。 特别地，本发明提供了编码HE4a的核酸序列，并且还提供了通过检测对具有天然存在于可溶性和/或可溶性的分子的HE4a多肽的特异性抗体的反应性来筛选受试者中恶性病症的存在的方法。 来自这样的受试者的样品中的细胞表面形式，以及使用HE4a核苷酸序列的杂交筛选以及其它相关优点。
-
-
-
-
-
-
-
-
-
Search Results
95
records
(took 0.07 seconds)
